III Spanish Consensus Conference on Helicobacter pylori infection;III Conferencia Española de Consenso sobre la infección por Helicobacter pylori

Gastroenterologia y Hepatologia

Volumn 36, Issue 5, 2013, Pages 340-374

  Gisbert, Javier P ^a   Calvet, Xavier ^b   Bermejo, Fernando ^c   Boixeda, Daniel ^d   Bory, Felipe ^e   Bujanda, Luis ^f   Castro Fernández, Manuel ^g   Dominguez Muñoz, Enrique ^h   Elizalde, Juan Ignasi ^b   Forné, Montserrat ^b   Gené, Emili ^b   Gomollón, Fernando ⁱ   Lanas, Ángel ^j   Martín de Argila, Carlos ^d   McNicholl, Adrián G ^a   Mearin, Fermín ^j   Molina Infante, Javier ^k   Montoro, Miguel ^l   Pajares, José María ^a   Pérez Aisa, Angeles ^m   Pérez Trallero, Emilio ⁿ   Sánchez Delgado, Jordi ^b   more..

^a Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^g HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^h Instituto de Salud Carlos III   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^j CENTRO MÉDICO TEKNON   (Spain)

^k HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^l HOSPITAL SAN JORGE   (Spain)

^m Servicio de Aparato Digestivo   (Spain)

ⁿ HOSPITAL DONOSTIA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONSENSUS DEVELOPMENT; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN;

HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS;

EID: 84877587639     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2013.01.011     Document Type: Article

References (326)

1. Sainz R., Borda F., Dominguez E., Gisbert J.P. Helicobacter pylori infection. The Spanish consensus report. The Spanish Consensus Conference Group. Rev Esp Enferm Dig 1999, 91:777-784.
2. Gisbert J.P., Calvet X., Gomollon F., Sainz R. Treatment for the eradication of Helicobacter pylori. Recommendations of the Spanish Consensus Conference. Med Clin (Barc) 2000, 114:185-195.
3. Mones J., Gisbert J.P., Borda F., Dominguez-Munoz E. Indications, diagnostic tests and Helicobacter pylori eradication therapy. Recommendations by the 2nd Spanish Consensus Conference. Rev Esp Enferm Dig 2005, 97:348-374.
4. Gisbert J.P., Calvet X., Gomollon F., Mones J. Eradication treatment of Helicobacter pylori. Recommendations of the II Spanish Consensus Conference. Med Clin (Barc) 2005, 125:301-316.
5. Gisbert J.P., Alonso-Coello P., Pique J.M. How can we find, design, evaluate and use clinical practice guidelines?. Gastroenterol Hepatol 2008, 31:239-257.
6. Dalkey N. Experimental Study of Group Opinion-Delphi Method. Features 1969, 1:408-426.
7. Canadian Association of Gastroenterology Policy on the Application for, and Implementation of, Clinical Practice Guidelines. Canadian Association of Gastroenterology 2008 [consultado 26 Nov 2012]. Disponible en: . http://wwwcag-acgorg/uploads/cpg%20guidelines%20v17june2008revpdf.
8. Gisbert J.P., Pajares J.M. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer?. Aliment Pharmacol Ther 2005, 21:795-804.
9. Ford A.C., Delaney B.C., Forman D., Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006, CD003840.
10. Tulassay Z., Stolte M., Sjolund M., Engstrand L., Butruk E., Malfertheiner P., et al. Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients. Eur J Gastroenterol Hepatol 2008, 20:526-536.
11. Gisbert J.P., Khorrami S., Carballo F., Calvet X., Gene E., Dominguez-Munoz J.E. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev 2004, CD004062.
12. Gisbert J.P., Calvet X., Cosme A., Almela P., Feu F., Bory F., et al. Long-Term Follow-Up of 1.000 patients cured of Helicobacter pylori infection following an episode of peptic ulcer bleeding. Am J Gastroenterol 2012, 107:1197-1204.
13. Gisbert J.P., Pajares J.M. Helicobacter pylori infection and gastric outlet obstruction -prevalence of the infection and role of antimicrobial treatment. Aliment Pharmacol Ther 2002, 16:1203-1208.
14. Gisbert J.P., Pajares J.M. Helicobacter pylori infection and perforated peptic ulcer prevalence of the infection and role of antimicrobial treatment. Helicobacter 2003, 8:159-167.
15. Gisbert J.P., Boixeda D., de Argila C.M., Bermejo F., Redondo C., de Rafael L. Erosive duodenitis: prevalence of Helicobacter pylori infection and response to eradication therapy with omeprazole plus two antibiotics. Eur J Gastroenterol Hepatol 1997, 9:957-962.
16. Gisbert J.P., Calvet X., Ferrandiz J., Mascort J., Alonso-Coello P., Mar M. Clinical practice guideline on the management of patients with dyspepsia. Update 2012. Gastroenterol Hepatol 2012, 35:725.
17. Gisbert J.P., Calvet X., Ferrandiz J., Mascort J., Alonso-Coello P., Marzo M. Clinical practice guideline on the management of patients with dyspepsia. Update 2012. Aten Primaria 2012, 44:727.
18. Gisbert J.P., Pajares J.M. Helicobacter pylori «test-and-treat» strategy for dyspeptic patients. Scand J Gastroenterol 1999, 34:644-652.
19. Gisbert JP, Calvet X. Helicobacter pylori «Test-and-Treat» strategy for management of dyspepsia: a comprehensive review. Clinical and Translational Gastroenterology. 2013;4:e32.
20. Moayyedi P., Zilles A., Clough M., Hemingbrough E., Chalmers D.M., Axon A.T. The effectiveness of screening and treating Helicobacter pylori in the management of dyspepsia. Eur J Gastroenterol Hepatol 1999, 11:1245-1250.
21. Joosen E.A., Reininga J.H., Manders J.M., ten Ham J.C., de Boer W.A. Costs and benefits of a test-and-treat strategy in Helicobacter pylori-infected subjects: a prospective intervention study in general practice. Eur J Gastroenterol Hepatol 2000, 12:319-325.
22. Madisch A., Hotz J., Grabowski G., Guth A., Malfertheiner P., Plein K., et al. Efficacy of Helicobacter pylori eradication in uninvestigated chronic dyspeptic staff members of a large factory: a prospective, long-term, follow-up, workplace outcome study. Eur J Gastroenterol Hepatol 2002, 14:61-69.
23. Farkkila M., Sarna S., Valtonen V., Sipponen P. Does the 'test-and-treat' strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients. Scand J Gastroenterol 2004, 39:327-335.
24. Gisbert J.P., Badia X., Roset M., Pajares J.M. The TETRA study: a prospective evaluation of Helicobacter pylori 'test-and-treat' strategy on 736 patients in clinical practice. Helicobacter 2004, 9:28-38.
25. Heaney A., Collins J.S., Watson R.G., McFarland R.J., Bamford K.B., Tham T.C. A prospective randomised trial of a «test and treat» policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic. Gut 1999, 45:186-190.
26. Jones R., Tait C., Sladen G., Weston-Baker J. A trial of a test-and-treat strategy for Helicobacter pylori positive dyspeptic patients in general practice. Int J Clin Pract 1999, 53:413-416.
27. Lassen A.T., Pedersen F.M., Bytzer P., Schaffalitzky de Muckadell O.B. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial. Lancet 2000, 356:455-460.
28. McColl K.E., Murray L.S., Gillen D., Walker A., Wirz A., Fletcher J., et al. Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H. pylori testing alone in the management of dyspepsia. BMJ 2002, 324:999-1002.
29. Arents N.L., Thijs J.C., van Zwet A.A., Oudkerk Pool M., Gotz J.M., van de Werf G.T., et al. Approach to treatment of dyspepsia in primary care: a randomized trial comparing «test-and-treat» with prompt endoscopy. Arch Intern Med 2003, 163:1606-1612.
30. Hu W.H., Lam S.K., Lam C.L., Wong W.M., Lam K.F., Lai K.C., et al. Comparison between empirical prokinetics. Helicobacter test-and-treat and empirical endoscopy in primary-care patients presenting with dyspepsia: a one-year study. World J Gastroenterol 2006, 12:5010-5016.
31. Mahadeva S., Chia Y.C., Vinothini A., Mohazmi M., Goh K.L. Cost-effectiveness of and satisfaction with a Helicobacter pylori «test and treat» strategy compared with prompt endoscopy in young Asians with dyspepsia. Gut 2008, 57:1214-1220.
32. Duggan A.E., Elliott C.A., Miller P., Hawkey C.J., Logan R.F. Clinical trial: a randomized trial of early endoscopy. Helicobacter pylori testing and empirical therapy for the management of dyspepsia in primary care. Aliment Pharmacol Ther 2009, 29:55-68.
33. Delaney B., Ford A.C., Forman D., Moayyedi P., Qume M. WITHDRAWN: Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2009, CD001961.
34. Ford A.C., Qume M., Moayyedi P., Arents N.L., Lassen A.T., Logan R.F., et al. Helicobacter pylori «test and treat» or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 2005, 128:1838-1844.
35. Manes G., Menchise A., de Nucci C., Balzano A. Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment. BMJ 2003, 326:1118.
36. Jarbol D.E., Kragstrup J., Stovring H., Havelund T., Schaffalitzky de Muckadell O.B. Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial. Am J Gastroenterol 2006, 101:1200-1208.
37. Delaney B.C., Qume M., Moayyedi P., Logan R.F., Ford A.C., Elliott C., et al. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). BMJ 2008, 336:651-654.
38. Ford A.C., Moayyedi P., Jarbol D.E., Logan R.F., Delaney B.C. Meta-analysis: Helicobacter pylori 'test and treat' compared with empirical acid suppression for managing dyspepsia. Aliment Pharmacol Ther 2008, 28:534-544.
39. Moayyedi P., Deeks J., Talley N.J., Delaney B., Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003, 98:2621-2626.
40. Laine L., Schoenfeld P., Fennerty M.B. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001, 134:361-369.
41. Gisbert J.P., Boixeda D., Martin de Argila C., Garcia Plaza A. Helicobacter pylori and non-ulcer dyspepsia: a pending matter. Rev Esp Enferm Dig 1998, 90:441-453.
42. Gisbert J.P., McNicholl A. Infección por Helicobacter pylori en España: ¿Está disminuyendo realmente su prevalencia?. Gastroenterol Hepatol 2012, 35:103.
43. Calvet X., Gisbert J.P. Estrategia test and treat en la infección por H. pylori. ¿Dónde, cuándo y a quién?. Gastroenterología Práctica 2004, 17:4-12.
44. Gillen D., McColl K.E. Does concern about missing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55?. Am J Gastroenterol 1999, 94:75-79.
45. Christie J., Shepherd N.A., Codling B.W., Valori R.M. Gastric cancer below the age of 55: implications for screening patients with uncomplicated dyspepsia. Gut 1997, 41:513-517.
46. Breslin N.P., Thomson A.B., Bailey R.J., Blustein P.K., Meddings J., Lalor E., et al. Gastric cancer and other endoscopic diagnoses in patients with benign dyspepsia. Gut 2000, 46:93-97.
47. Bustamante M., Ferrando M.J., Devesa F., Borghol A. The prediction of the endoscopic diagnosis in the dyspepsia patient: the value of the predominating presenting symptom and the initial clinical presumption. Gastroenterol Hepatol 2000, 23:66-70.
48. Wallace M.B., Durkalski V.L., Vaughan J., Palesch Y.Y., Libby E.D., Jowell P.S., et al. Age and alarm symptoms do not predict endoscopic findings among patients with dyspepsia: a multicentre database study. Gut 2001, 49:29-34.
49. Chiba N., Van Zanten S.J., Sinclair P., Ferguson R.A., Escobedo S., Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002, 324:1012-1016.
50. Dyspepia: managing dyspepsia in adults in primary care. [Consultado 26 Nov 2012]. Disponible en: . http://www.nice.org.uk/CG017NICEguideline.
51. Talley N.J., Vakil N. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005, 100:2324-2337.
52. Chey W.D., Wong B.C. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007, 10:1808-1825.
53. Gisbert J.P., Pajares J.M. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection -- a critical review. Aliment Pharmacol Ther 2004, 20:1001-1017.
54. Gisbert J.P., de la Morena F., Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am J Gastroenterol 2006, 101:1921-1930.
55. Feldman R.A., Deeks J.J., Evans S.J. Multi-laboratory comparison of eight commercially available Helicobacter pylori serology kits. Helicobacter pylori Serology Study Group. Eur J Clin Microbiol Infect Dis 1995, 14:428-433.
56. Marshall J.K., Armstrong D., O'Brien B.J. Test and treat strategies for Helicobacter pylori in uninvestigated dyspepsia: a Canadian economic analysis. Can J Gastroenterol 2000, 14:379-388.
57. Chey W.D., Fendrick A.M. Noninvasive Helicobacter pylori testing for the «test-and-treat» strategy: a decision analysis to assess the effect of past infection on test choice. Arch Intern Med 2001, 161:2129-2132.
58. Drossman D.A. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006, 130:1377-1390.
59. Moayyedi P., Soo S., Deeks J., Delaney B., Harris A., Innes M., et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006, CD002096.
60. Jin X., Li Y.M. Systematic review and meta-analysis from Chinese literature: the association between Helicobacter pylori eradication and improvement of functional dyspepsia. Helicobacter 2007, 12:541-546.
61. Mazzoleni L.E., Sander G.B., Francesconi C.F., Mazzoleni F., Uchoa D.M., De Bona L.R., et al. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med 2011, 171:1929-1936.
62. Huang J.Q., Sridhar S., Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002, 359:14-22.
63. Vergara M., Catalan M., Gisbert J.P., Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005, 21:1411-1418.
64. de Leest H.T., Steen K.S., Lems W.F., Bijlsma J.W., van de Laar M.A., Huisman A.M., et al. Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial. Helicobacter 2007, 477-485.
65. Chan F.K., Chung S.C., Suen B.Y., Lee Y.T., Leung W.K., Leung V.K., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001, 344:967-973.
66. Lai K.C., Lam S.K., Chu K.M., Wong B.C., Hui W.M., Hu W.H., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002, 346:2033-2038.
67. Chan F.K.L., Ching J., Suen B., Tse Y.K., Wu J.C., Sung J.J. Effect of H. pylori eradication on the long-term incidence of recurrent ulcer bleeding in high-risk aspirin users: a 10-year prospective cohort study. Gastroenterology 2011, 140(Suppl 1):173-174.
68. Fletcher E.H., Johnston D.E., Fisher C.R., Koerner R.J., Newton J.L., Gray C.S. Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol Ther 2010, 32:831-839.
69. Gisbert J.P. Is gastric lymphoma an infectious disease?. Med Clin (Barc) 1998, 110:56-61.
70. Isaacson P.G., Spencer J. Is gastric lymphoma an infectious disease?. Hum Pathol 1993, 24:569-570.
71. Asenjo L.M., Gisbert J.P. Prevalence of Helicobacter pylori infection in gastric MALT lymphoma: a systematic review. Rev Esp Enferm Dig 2007, 99:398-404.
72. Zullo A., Hassan C., Cristofari F., Perri F., Morini S. Gastric low-grade mucosal-associated lymphoid tissue-lymphoma: Helicobacter pylori and beyond. World J Gastrointest Oncol 2010, 2:181-186.
73. Gisbert J.P., Calvet X. Review article: common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphoma. Aliment Pharmacol Ther 2011, 34:1047-1062.
74. Ruskone-Fourmestraux A., Fischbach W., Aleman B.M., Boot H., Du M.Q., Megraud F., et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011, 60:747-758.
75. Morris G.J., Dotan E., Smith M.R., Hagemeister F.B., Brereton H.D. Gastric mucosa-associated lymphoid tissue lymphoma. Semin Oncol 2010, 37:183-187.
76. Zullo A., Hassan C., Cristofari F., Andriani A., de Francesco V., Ierardi E., et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol 2010, 8:105-110.
77. Fukase K., Kato M., Kikuchi S., Inoue K., Uemura N., Okamoto S., et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008, 372:392-397.
78. Piazuelo M.B., Epplein M., Correa P. Gastric cancer: an infectious disease. Infect Dis Clin North Am 2010, 24:853-869.
79. de Vries A.C., Kuipers E.J. Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther 2007, 26(Suppl 2):25-35.
80. Basso D., Zambon C.F., Letley D.P., Stranges A., Marchet A., Rhead J.L., et al. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology 2008, 135:91-99.
81. Uemura N., Mukai T., Okamoto S., Yamaguchi S., Mashiba H., Taniyama K., et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997, 6:639-642.
82. Hamajima N., Goto Y., Nishio K., Tanaka D., Kawai S., Sakakibara H., et al. Helicobacter pylori eradication as a preventive tool against gastric cancer. Asian Pac J Cancer Prev 2004, 5:246-252.
83. Brenner H., Arndt V., Sturmer T., Stegmaier C., Ziegler H., Dhom G. Individual and joint contribution of family history and Helicobacter pylori infection to the risk of gastric carcinoma. Cancer 2000, 88:274-279.
84. Chen M.J., Wu D.C., Ko Y.C., Chiou Y.Y. Personal history and family history as a predictor of gastric cardiac adenocarcinoma risk: a case-control study in Taiwan. Am J Gastroenterol 2004, 99:1250-1257.
85. Foschi R., Lucenteforte E., Bosetti C., Bertuccio P., Tavani A., la Vecchia C., et al. Family history of cancer and stomach cancer risk. Int J Cancer 2008, 123:1429-1432.
86. Kondo T., Toyoshima H., Tsuzuki Y., Hori Y., Yatsuya H., Tamakoshi K., et al. Aggregation of stomach cancer history in parents and offspring in comparison with other sites. Int J Epidemiol 2003, 32:579-583.
87. Munoz N., Plummer M., Vivas J., Moreno V., de Sanjose S., Lopez G., et al. A case-control study of gastric cancer in Venezuela. Int J Cancer 2001, 93:417-423.
88. Shin C.M., Kim N., Yang H.J., Cho S.I., Lee H.S., Kim J.S., et al. Stomach cancer risk in gastric cancer relatives: interaction between Helicobacter pylori infection and family history of gastric cancer for the risk of stomach cancer. J Clin Gastroenterol 2010, 44:34-39.
89. Rokkas T., Sechopoulos P., Pistiolas D., Margantinis G., Koukoulis G. Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis. Eur J Gastroenterol Hepatol 2010, 22:1128-1133.
90. Malfertheiner P., Sipponen P., Naumann M., Moayyedi P., Megraud F., Xiao S.D., et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 2005, 100:2100-2115.
91. de Vries A.C., van Grieken N.C., Looman C.W., Casparie M.K., de Vries E., Meijer G.A., et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008, 134:945-952.
92. Wang J., Xu L., Shi R., Huang X., Li S.W., Huang Z., et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 2011, 83:253-260.
93. Leung W.K., Lin S.R., Ching J.Y., To K.F., Ng E.K., Chan F.K., et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004, 53:1244-1249.
94. Wong B.C., Lam S.K., Wong W.M., Chen J.S., Zheng T.T., Feng R.E., et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004, 291:187-194.
95. Malfertheiner P., Megraud F., O'Morain C.A., Atherton J., Axon A.T., Bazzoli F., et al. Management of Helicobacter pylori infection--the Maastricht IV/Florence Consensus Report. Gut 2012, 61:646-664.
96. Tulassay Z., Stolte M., Engstrand L., Butruk E., Malfertheiner P., Dite P., et al. Twelve-month endoscopic and histological analysis following proton-pump inhibitor-based triple therapy in Helicobacter pylori-positive patients with gastric ulcers. Scand J Gastroenterol 2010, 45:1048-1058.
97. González CA, Sanz-Anquela JM, Gisbert JP, Correa P. Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. Int J Cancer. 2013. doi: 10.1002/ijc.28003. [Epub ahead of print].
98. Gisbert J.P., Pajares J.M. Should Helicobacter pylori infection be treated prior to long-term proton pump inhibitor therapy?. Med Clin (Barc) 2001, 117:793-797.
99. Kuipers E.J., Lundell L., Klinkenberg-Knol E.C., Havu N., Festen H.P., Liedman B., et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996, 334:1018-1022.
100. Yang H.B., Sheu B.S., Wang S.T., Cheng H.C., Chang W.L., Chen W.Y. H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole. Am J Gastroenterol 2009, 104:1642-1649.
101. Hagiwara T., Mukaisho K., Nakayama T., Sugihara H., Hattori T. Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori. Gut 2011, 60:624-630.
102. Hamzat H., Sun H., Ford J.C., Macleod J., Soiza R.L., Mangoni A.A. Inappropriate prescribing of proton pump inhibitors in older patients: effects of an educational strategy. Drugs Aging 2012, 29:681-690.
103. Batuwitage B.T., Kingham J.G., Morgan N.E., Bartlett R.L. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007, 83:66-68.
104. Liu K., Kaffes A.J. Iron deficiency anaemia: a review of diagnosis, investigation and management. Eur J Gastroenterol Hepatol 2012, 24:109-116.
105. Fernandez-Banares F., Monzon H., Forne M. A short review of malabsorption and anemia. World J Gastroenterol 2009, 15:4644-4652.
106. Muhsen K., Cohen D. Helicobacter pylori infection and iron stores: a systematic review and meta-analysis. Helicobacter 2008, 13:323-340.
107. Qu X.H., Huang X.L., Xiong P., Zhu C.Y., Huang Y.L., Lu L.G., et al. Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis. World J Gastroenterol 2010, 16:886-896.
108. Huang X., Qu X., Yan W., Huang Y., Cai M., Hu B., et al. Iron deficiency anaemia can be improved after eradication of Helicobacter pylori. Postgrad Med J 2010, 86:272-278.
109. Yuan W., Li Y., Yang K., Ma B., Guan Q., Wang D., et al. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol 2010, 45:665-676.
110. George J.N. Definition, diagnosis and treatment of immune thrombocytopenic purpura. Haematologica 2009, 94:759-762.
111. Franchini M., Plebani M., Montagnana M., Veneri D., Lippi G. Pathogenesis, laboratory, and clinical characteristics of Helicobacter pylori-associated immune thrombocytopenic purpura. Adv Clin Chem 2010, 52:131-144.
112. Franchini M., Cruciani M., Mengoli C., Pizzolo G., Veneri D. Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. J Antimicrob Chemother 2007, 60:237-246.
113. Arnold D.M., Bernotas A., Nazi I., Stasi R., Kuwana M., Liu Y., et al. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica 2009, 94:850-856.
114. Stasi R., Sarpatwari A., Segal J.B., Osborn J., Evangelista M.L., Cooper N., et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009, 113:1231-1240.
115. Pietroiusti A., Galante A., Magrini A., Bergamaschi A. Helicobacter pylori interference with micronutrients and orally administered drugs: a new mechanism explaining its role in extragastric disorders. Mini Rev Med Chem 2008, 8:135-141.
116. Andres E., Federici L., Affenberger S., Vidal-Alaball J., Loukili N.H., Zimmer J., et al. B12 deficiency: a look beyond pernicious anemia. J Fam Pract 2007, 56:537-542.
117. Carmel R., Aurangzeb I., Qian D. Associations of food-cobalamin malabsorption with ethnic origin, age, Helicobacter pylori infection, and serum markers of gastritis. Am J Gastroenterol 2001, 96:63-70.
118. Kaptan K., Beyan C., Ural A.U., Cetin T., Avcu F., Gulsen M., et al. Helicobacter pylori--is it a novel causative agent in Vitamin B12 deficiency?. Arch Intern Med 2000, 160:1349-1353.
119. Andres E., Dali-Youcef N., Vogel T., Serraj K., Zimmer J. Oral cobalamin (vitamin B(12)) treatment. An update. Int J Lab Hematol 2009, 31:1-8.
120. Lahner E., Persechino S., Annibale B. Micronutrients (Other than iron) and Helicobacter pylori infection: a systematic review. Helicobacter 2012, 17:1-15.
121. Rebora A., Drago F., Picciotto A. Helicobacter pylori in patients with rosacea. Am J Gastroenterol 1994, 89:1603-1604.
122. Boixeda de Miquel D., Vazquez Romero M., Vazquez Sequeiros E., Foruny Olcina J.R., Boixeda de Miquel P., Lopez San Roman A., et al. Effect of Helicobacter pylori eradication therapy in rosacea patients. Rev Esp Enferm Dig 2006, 98:501-509.
123. Zandi S., Shamsadini S., Zahedi M.J., Hyatbaksh M. Helicobacter pylori and rosacea. East Mediterr Health J 2003, 9:167-171.
124. Diaz C., O'Callaghan C.J., Khan A., Ilchyshyn A. Rosacea: a cutaneous marker of Helicobacter pylori infection? Results of a pilot study. Acta Derm Venereol 2003, 83:282-286.
125. Lazaridou E., Giannopoulou C., Fotiadou C., Vakirlis E., Trigoni A., Ioannides D. The potential role of microorganisms in the development of rosacea. J Dtsch Dermatol Ges 2011, 9:21-25.
126. Herr H., You C.H. Relationship between Helicobacter pylori and rosacea: it may be a myth. J Korean Med Sci 2000, 15:551-554.
127. Bamford J.T., Tilden R.L., Blankush J.L., Gangeness D.E. Effect of treatment of Helicobacter pylori infection on rosacea. Arch Dermatol 1999, 135:659-663.
128. Abram K., Silm H., Maaroos H.I., Oona M. Risk factors associated with rosacea. J Eur Acad Dermatol Venereol 2010, 24:565-571.
129. Lazaridou E., Apalla Z., Sotiraki S., Ziakas N.G., Fotiadou C., Ioannides D. Clinical and laboratory study of rosacea in northern Greece. J Eur Acad Dermatol Venereol 2010, 24:410-414.
130. Lazaridou E., Fotiadou C., Ziakas N.G., Giannopoulou C., Apalla Z., Ioannides D. Clinical and laboratory study of ocular rosacea in northern Greece. J Eur Acad Dermatol Venereol 2011, 25:1428-1431.
131. Szlachcic A., Sliwowski Z., Karczewska E., Bielanski W., Pytko-Polonczyk J., Konturek S.J. Helicobacter pylori and its eradication in rosacea. J Physiol Pharmacol 1999, 50:777-786.
132. Baldwin H.E. Diagnosis and treatment of rosacea: state of the art. J Drugs Dermatol 2012, 11:725-730.
133. di Campli C., Gasbarrini A., Nucera E., Franceschi F., Ojetti V., Sanz Torre E., et al. Beneficial effects of Helicobacter pylori eradication on idiopathic chronic urticaria. Dig Dis Sci 1998, 43:1226-1229.
134. Wedi B., Wagner S., Werfel T., Manns M.P., Kapp A. Prevalence of Helicobacter pylori-associated gastritis in chronic urticaria. Int Arch Allergy Immunol 1998, 116:288-294.
135. Erel F., Sener O., Erdil A., Karaayvaz M., Gur G., Caliskaner Z., et al. Impact of Helicobacter pylori and Giardia lamblia infections on chronic urticaria. J Investig Allergol Clin Immunol 2000, 10:94-97.
136. Dauden E., Jimenez-Alonso I., Garcia-Diez A. Helicobacter pylori and idiopathic chronic urticaria. Int J Dermatol 2000, 39:446-452.
137. Schnyder B., Helbling A., Pichler W.J. Chronic idiopathic urticaria: natural course and association with Helicobacter pylori infection. Int Arch Allergy Immunol 1999, 119:60-63.
138. Gaig P., Garcia-Ortega P., Enrique E., Papo M., Quer J.C., Richard C. Efficacy of the eradication of Helicobacter pylori infection in patients with chronic urticaria. A placebo-controlled double blind study. Allergol Immunopathol (Madr) 2002, 30:255-258.
139. Federman D.G., Kirsner R.S., Moriarty J.P., Concato J. The effect of antibiotic therapy for patients infected with Helicobacter pylori who have chronic urticaria. J Am Acad Dermatol 2003, 49:861-864.
140. Valsecchi R., Pigatto P. Chronic urticaria and Helicobacter pylori. Acta Derm Venereol 1998, 78:440-442.
141. Wustlich S., Brehler R., Luger T.A., Pohle T., Domschke W., Foerster E. Helicobacter pylori as a possible bacterial focus of chronic urticaria. Dermatology 1999, 198:130-132.
142. Hook-Nikanne J., Varjonen E., Harvima R.J., Kosunen T.U. Is Helicobacter pylori infection associated with chronic urticaria?. Acta Derm Venereol 2000, 80:425-426.
143. Moreira A., Rodrigues J., Delgado L., Fonseca J., Vaz M. Is Helicobacter pylori infection associated with chronic idiopathic urticaria?. Allergol Immunopathol (Madr) 2003, 31:209-214.
144. Liutu M., Kalimo K., Kalimo H., Uksila J., Leino R. Mast cells and IgE-containing cells in gastric mucosa of Helicobacter pylori infected and non-infected patients with chronic urticaria. J Eur Acad Dermatol Venereol 2004, 18:69-72.
145. Baskan E.B., Turker T., Gulten M., Tunali S. Lack of correlation between Helicobacter pylori infection and autologous serum skin test in chronic idiopathic urticaria. Int J Dermatol 2005, 44:993-995.
146. Akashi R., Ishiguro N., Shimizu S., Kawashima M. Clinical study of the relationship between Helicobacter pylori and chronic urticaria and prurigo chronica multiformis: effectiveness of eradication therapy for Helicobacter pylori. J Dermatol 2011, 38:761-766.
147. Shakouri A., Compalati E., Lang D.M., Khan D.A. Effectiveness of Helicobacter pylori eradication in chronic urticaria: evidence-based analysis using the grading of recommendations assessment, development, and evaluation system. Curr Opin Allergy Clin Immunol 2010, 10:362-369.
148. Campanati A., Gesuita R., Giannoni M., Piraccini F., Sandroni L., Martina E., et al. Role of small intestinal bacterial overgrowth and Helicobacter pylori infection in chronic spontaneous urticaria: a prospective analysis. Acta Derm Venereol 2012, 93:161-164.
149. Gisbert J.P., Boixeda D., Martin de Argila C., Garcia Plaza A. Helicobacter pylori and duodenal ulcer: a causal relation or mere association?. Rev Clin Esp 1997, 197:693-702.
150. Schottker B., Adamu M.A., Weck M.N., Brenner H. Helicobacter pylori infection is strongly associated with gastric and duodenal ulcers in a large prospective study. Clin Gastroenterol Hepatol 2012, 10:487-493.
151. Huang J.Q., Sridhar S., Chen Y., Hunt R.H. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998, 114:1169-1179.
152. Harvey R.F., Lane J.A., Nair P., Egger M., Harvey I., Donovan J., et al. Clinical trial: prolonged beneficial effect of Helicobacter pylori eradication on dyspepsia consultations - the Bristol Helicobacter Project. Aliment Pharmacol Ther 2010, 32:394-400.
153. Fuccio L., Zagari R.M., Eusebi L.H., Laterza L., Cennamo V., Ceroni L., et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?. Ann Intern Med 2009, 151:121-128.
154. Graham D.Y. The only good Helicobacter pylori is a dead Helicobacter pylori. Lancet 1997, 350:70-71.
155. Gisbert J.P., Pajares J.M. 13C-urea breath test in the management of Helicobacterpylori infection. Dig Liver Dis 2005, 37:899-906.
156. Dominguez-Munoz J.E., Leodolter A., Sauerbruch T., Malfertheiner P. A citric acid solution is an optimal test drink in the 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Gut 1997, 40:459-462.
157. Calvet X., Sanchez-Delgado J., Montserrat A., Lario S., Ramirez-Lazaro M.J., Quesada M., et al. Accuracy of diagnostic tests for Helicobacter pylori: a reappraisal. Clin Infect Dis 2009, 48:1385-1391.
158. Eggers R.H., Kukp A., Tegeler R., Lüdtke F.E., Lepsien G., Meyer B. A methodological analysis of the 13C-urea breath tests for detection of Helicobacter pylori infections: high sensitivity and specificity within 30minutes using 75mg of 13C-urea. Eur J Gastroenterol Hepatol 1990, 2:437-444.
159. Graham D.Y., Runke D., Anderson S.Y., Malaty H.M., Klein P.D. Citric acid as the test meal for the 13C-urea breath test. Am J Gastroenterol 1999, 94:1214-1217.
160. Leodolter A., Dominguez-Munoz J.E., Von Arnim U., Malfertheiner P. Citric acid or orange juice for the 13C-urea breath test: the impact of pH and gastric emptying. Aliment Pharmacol Ther 1999, 13:1057-1062.
161. Calvet X., Lario S., Ramirez-Lazaro M.J., Montserrat A., Quesada M., Reeves L., et al. Comparative accuracy of 3 monoclonal stool tests for diagnosis of Helicobacter pylori infection among patients with dyspepsia. Clin Infect Dis 2010, 50:323-328.
162. Calvet X., Lario S., Ramirez-Lazaro M.J., Montserrat A., Quesada M., Reeves L., et al. Accuracy of monoclonal stool tests for determining cure of Helicobacter pylori infection after treatment. Helicobacter 2010, 15:201-205.
163. Lehours P., Ruskone-Fourmestraux A., Lavergne A., Cantet F., Megraud F. Which test to use to detect Helicobacter pylori infection in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma?. Am J Gastroenterol 2003, 98:291-295.
164. Kokkola A., Rautelin H., Puolakkainen P., Sipponen P., Farkkila M., Haapiainen R., et al. Positive result by serology indicates active Helicobacter pylori infection in patients with atrophic gastritis. J Clin Microbiol 1998, 36:1808-1810.
165. Ramirez-Lazaro M.J., Lario S., Casalots A., Sanfeliu E., Boix L., Garcia-Iglesias P., et al. Real-time PCR improves Helicobacter pylori detection in patients with peptic ulcer bleeding. PLoS One 2011, 6:e20009.
166. Levine A., Shevah O., Shabat-Sehayek V., Aeed H., Boaz M., Moss S.F., et al. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole. Aliment Pharmacol Ther 2004, 20:117-122.
167. Ozturk E., Yesilova Z., Ilgan S., Ozguven M., Dagalp K. Performance of acidified 14C-urea capsule breath test during pantoprazole and ranitidine treatment. J Gastroenterol Hepatol 2009, 24:1248-1251.
168. Erzin Y., Altun S., Dobrucali A., Aslan M., Erdamar S., Dirican A., et al. Evaluation of two enzyme immunoassays for detecting Helicobacter pylori in stool specimens of dyspeptic patients after eradication therapy. J Med Microbiol 2005, 54(Pt 9):863-866.
169. Asfeldt A.M., Lochen M.L., Straume B., Steigen S.E., Florholmen J., Goll R., et al. Accuracy of a monoclonal antibody-based stool antigen test in the diagnosis of Helicobacter pylori infection. Scand J Gastroenterol 2004, 39:1073-1077.
170. Graham D.Y., Opekun A.R., Hammoud F., Yamaoka Y., Reddy R., Osato M.S., et al. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol 2003, 98:1005-1009.
171. Laine L., Estrada R., Trujillo M., Knigge K., Fennerty M.B. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 1998, 129:547-550.
172. Glupczynski Y., Burette A., Labbe M., Deprez C., de Reuck M., Deltenre M. Campylobacter pylori-associated gastritis: a double-blind placebo-controlled trial with amoxycillin. Am J Gastroenterol 1988, 83:365-372.
173. Morgan D., Kraft W., Bender M., Pearson A. Nitrofurans in the treatment of gastritis associated with Campylobacter pylori. The Gastrointestinal Physiology Working Group of Cayetano Heredia and The Johns Hopkins Universities. Gastroenterology 1988, 95:1178-1184.
174. Tytgat G.N., Rauws E.A., de Koster E.H. Campylobacter pylori. Diagnosis and treatment. J Clin Gastroenterol 1989, 11(Suppl 1):S49-S53.
175. Axon A.T. Campylobacter pylori--therapy review. Scand J Gastroenterol Suppl 1989, 160:35-38.
176. Vakil N., Zullo A., Ricci C., Hassan C., Vaira D. Duplicate breath testing to confirm eradication of Helicobacter pylori: incremental benefit and cost in 419 patients. Aliment Pharmacol Ther 2008, 28:1304-1308.
177. Bytzer P., Dahlerup J.F., Eriksen J.R., Jarbol D.E., Rosenstock S., Wildt S. Diagnosis and treatment of Helicobacter pylori infection. Dan Med Bull 2011, 58:C4271.
178. Phull P.S., Halliday D., Price A.B., Jacyna M.R. Absence of dyspeptic symptoms as a test of Helicobacter pylori eradication. BMJ 1996, 312:349-350.
179. McColl K.E., el-Nujumi A., Murray L.S., el-Omar E.M., Dickson A., Kelman A.W., et al. Assessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer. Gut 1998, 42:618-622.
180. Gene E., Calvet X., Azagra R. Diagnosis of Helicobacter pylori after triple therapy in uncomplicated duodenal ulcers--a cost-effectiveness analysis. Aliment Pharmacol Ther 2000, 14:433-442.
181. Lee J.H., Kim N., Chung J.I., Kang K.P., Lee S.H., Park Y.S., et al. Long-term follow up of Helicobacter pylori IgG serology after eradication and reinfection rate of H. pylori in South Korea. Helicobacter 2008, 13:288-294.
182. Gisbert J.P., Blanco M., Benito L.M., Pajares J.M. Value of quantitative serology for confirmation of Helicobacter pylori eradication: an 18-month follow-up study. Clin Infect Dis 2000, 30:976-980.
183. Mohar A., Ley C., Guarner J., Herrera-Goepfert R., Figueroa L.S., Halperin D., et al. Eradication rate of Helicobacter pylori in a Mexican population at high risk for gastric cancer and use of serology to assess cure. Am J Gastroenterol 2002, 97:2530-2535.
184. Laheij R.J., Witteman E.M., Bloembergen P., de Koning R.W., Jansen J.B., Verbeek A.L. Short-term follow-up by serology of patients given antibiotic treatment for Helicobacter pylori infection. J Clin Microbiol 1998, 36:1193-1196.
185. Fallone C.A., Loo V.G., Barkun A.N. Utility of serology in determining Helicobacter pylori eradication after therapy. Can J Gastroenterol 1998, 12:117-124.
186. Safe A.F., Warren B., Corfield A., McNulty C.A., Watson B., Mountford R.A., et al. Role of serology in monitoring treatment for Helicobacter pylori infection in elderly patients. Age Ageing 1993, 22:256-259.
187. Bermejo F., Boixeda D., Gisbert J.P., Sanz J.M., Canton R., Defarges V., et al. Concordance between noninvasive tests in detecting Helicobacter pylori and potential use of serology for monitoring eradication in gastric ulcer. J Clin Gastroenterol 2000, 31:137-141.
188. Gisbert J.P. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. Am J Gastroenterol 2005, 100:2083-2099.
189. Graham D.Y., Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010, 59:1143-1153.
190. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004, 53:1374-1384.
191. Pérez-Trallero E., Ramírez-Lázaro M.J., Villar H., Royo G., Montes M., Lario S., et al. Resistencia de Helicobacter pylori a diversos antibióticos: un estudio multicéntrico español. Gastroenterol Hepatol 2011, 34:236.
192. Megraud F., Coenen S., Versporten A., Kist M., Lopez-Brea M., Hirschl M.A., et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2012, 62:34-42.
193. Gisbert J.P., Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011, 34:1255-1268.
194. Gisbert J.P., McNicholl A.G. Maintenance of Helicobacter pylori eradication rates with triple therapy over 12 years in a Spanish hospital. Helicobacter 2012, 17:160-161.
195. Gene E., Calvet X., Azagra R., Gisbert J.P. Triple vs quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. Aliment Pharmacol Ther 2003, 18:543-544.
196. Gene E., Calvet X., Azagra R., Gisbert J.P. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther 2003, 17:1137-1143.
197. Luther J., Higgins P.D., Schoenfeld P.S., Moayyedi P., Vakil N., Chey W.D. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010, 105:65-73.
198. Malfertheiner P., Bazzoli F., Delchier J.C., Celinski K., Giguere M., Riviere M., et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011, 377:905-913.
199. Gisbert J.P., Calvet X., O'Connor A., Megraud F., O'Morain C.A. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010, 44:313-325.
200. Zullo A., de Francesco V., Hassan C., Morini S., Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007, 56:1353-1357.
201. Nyssen O.P., McNicholl A., Mégraud F., Savarino V., Oderda G., Fallone F., et al. Metaanálisis de la terapia secuencial frente a la triple terapia clásica para la erradicación de Helicobacter pylori. Gastroenterol Hepatol 2012, 35:107.
202. Sanchez-Delgado J., Calvet X., Bujanda L., Gisbert J.P., Tito L., Castro M. Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. Am J Gastroenterol 2008, 103:2220-2223.
203. Molina-Infante J., Perez-Gallardo B., Fernandez-Bermejo M., Hernandez-Alonso M., Vinagre G., Duenas C., et al. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010, 31:1077-1084.
204. Essa A.S., Kramer J.R., Graham D.Y., Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing «concomitant therapy» versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009, 14:109-118.
205. Gisbert J.P., Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther 2011, 34:604-617.
206. Gisbert J.P., Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012, 5:23-34.
207. Wu D.C., Hsu P.I., Wu J.Y., Opekun A.R., Kuo C.H., Wu I.C., et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol 2010, 8:36-41.
208. Molina-Infante J., Pazos-Pacheco C., Vinagre-Rodriguez G., Perez-Gallardo B., Duenas-Sadornil C., Hernandez-Alonso M., et al. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. Helicobacter 2012, 17:269-276.
209. McNicholl A.G., Marin A.C., Molina-Infante J., Castro-Fernandez M., Barrio J., Ducons J., et al. Randomized clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2013, En prensa.
210. Greenberg E.R., Anderson G.L., Morgan D.R., Torres J., Chey W.D., Bravo L.E., et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011, 378:507-514.
211. Huang Y.K., Wu M.C., Wang S.S., Kuo C.H., Lee Y.C., Chang L.L., et al. Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication. J Dig Dis 2012, 13:232-238.
212. Calvet X., Garcia N., Lopez T., Gisbert J.P., Gene E., Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000, 14:603-609.
213. Ford A., Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved?. Can J Gastroenterol 2003, 17(Suppl B):S36-S40.
214. Fuccio L., Minardi M.E., Zagari R.M., Grilli D., Magrini N., Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007, 147:553-562.
215. Flores H.B., Salvana A., Ang E.L.R., Estanislao N.I., Velasquez M.E., Ong J., et al. Duration of proton-pump inhibitor-based triple therapy for helicobacter pylori eradication: a meta-analysis. Gastroenterology 2010, 138(Suppl 1):M1138.
216. Villoria A., Garcia P., Calvet X., Gisbert J.P., Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008, 28:868-877.
217. Vallve M., Vergara M., Gisbert J.P., Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther 2002, 16:1149-1156.
218. Padol S., Yuan Y., Thabane M., Padol I.T., Hunt R.H. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006, 101:1467-1475.
219. Serrano D., Torrado S., Torrado-Santiago S., Gisbert J.P. The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/- pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments. Curr Drug Metab 2012, 13:1303-1312.
220. Ward M.B., Foster D.J. CYP2C19-guided design of a proton pump inhibitor dose regimen to avoid the need for pharmacogenetic individualization in H. pylori eradication. Eur J Clin Pharmacol 2011, 67:261-266.
221. McNicholl A.G., Linares P.M., Nyssen O.P., Calvet X., Gisbert J.P. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012, 36:414-425.
222. Zou J., Dong J., Yu X.F. Meta-analysis: the effect of supplementation with lactoferrin on eradication rates and adverse events during Helicobacter pylori eradication therapy. Helicobacter 2009, 14:119-127.
223. Sachdeva A., Nagpal J. Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication. Aliment Pharmacol Ther 2009, 29:720-730.
224. Tong J.L., Ran Z.H., Shen J., Zhang C.X., Xiao S.D. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007, 25:155-168.
225. Zou J., Dong J., Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter 2009, 14:97-107.
226. Wilhelm S.M., Johnson J.L., Kale-Pradhan P.B. Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. Ann Pharmacother 2011, 45:960-966.
227. Medeiros J.A., Goncalves T.M., Boyanova L., Pereira M.I., de Carvalho J.N., Pereira A.M., et al. Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone. Eur J Clin Microbiol Infect Dis 2011, 30:555-559.
228. Bekar O., Yilmaz Y., Gulten M. Kefir improves the efficacy and tolerability of triple therapy in eradicating Helicobacter pylori. J Med Food 2011, 14:344-347.
229. Yoon H., Kim N., Kim J.Y., Park S.Y., Park J.H., Jung H.C., et al. Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection. J Gastroenterol Hepatol 2011, 26:44-48.
230. Rosania R., Minenna M.F., Giorgio F., Facciorusso A., de Francesco V., Hassan C., et al. Probiotic multistrain treatment may eradicate Helicobacter pylori from the stomach of dyspeptics: a placebo-controlled pilot study. Inflamm Allergy Drug Targets 2012, 11:244-249.
231. Deguchi R., Nakaminami H., Rimbara E., Noguchi N., Sasatsu M., Suzuki T., et al. Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy. J Gastroenterol Hepatol 2012, 27:888-892.
232. Ozdil K., Calhan T., Sahin A., Senates E., Kahraman R., Yuzbasioglu B., et al. Levofloxacin based sequential and triple therapy compared with standard plus probiotic combination for Helicobacter pylori eradication. Hepatogastroenterology 2011, 58:1148-1152.
233. Manfredi M., Bizzarri B., Sacchero R.I., Maccari S., Calabrese L., Fabbian F., et al. Helicobacter pylori infection in clinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy. Helicobacter 2012, 17:254-263.
234. Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010, 32:1069-1079.
235. Lionetti E., Indrio F., Pavone L., Borrelli G., Cavallo L., Francavilla R. Role of probiotics in pediatric patients with Helicobacter pylori infection: a comprehensive review of the literature. Helicobacter 2010, 15:79-87.
236. Gisbert J.P., Pajares J.M. Review article: Helicobacter pylori «rescue» regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002, 16:1047-1057.
237. Nista E.C., Candelli M., Cremonini F., Cazzato I.A., di Caro S., Gabrielli M., et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003, 18:627-633.
238. Perri F., Festa V., Merla A., Barberani F., Pilotto A., Andriulli A. Randomized study of different «second-line» therapies for Helicobacter pylori infection after failure of the standard Maastricht triple therapy. Aliment Pharmacol Ther 2003, 18:815-820.
239. Watanabe Y., Aoyama N., Shirasaka D., Maekawa S., Kuroda K., Miki I., et al. Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 2003, 35:711-715.
240. Bilardi C., Dulbecco P., Zentilin P., Reglioni S., Iiritano E., Parodi A., et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol 2004, 2:997-1002.
241. Matsumoto Y., Miki I., Aoyama N., Shirasaka D., Watanabe Y., Morita Y., et al. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis 2005, 37:821-825.
242. Lee Y.C., Wu H.M., Chen T.H., Liu T.Y., Chiu H.M., Chang C.C., et al. A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures. Helicobacter 2006, 11:418-424.
243. Lee J.H., Hong S.P., Kwon C.I., Phyun L.H., Lee B.S., Song H.U., et al. The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2006, 48:19-24.
244. Marzio L., Coraggio D., Capodicasa S., Grossi L., Cappello G. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter 2006, 11:237-242.
245. Wong W.M., Gu Q., Chu K.M., Yee Y.K., Fung F.M., Tong T.S., et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006, 23:421-427.
246. Cheng H.C., Chang W.L., Chen W.Y., Yang H.B., Wu J.J., Sheu B.S. Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy. Helicobacter 2007, 12:359-363.
247. Gisbert J.P., Gisbert J.L., Marcos S., Moreno-Otero R., Pajares J.M. Levofloxacin- vs. ranitidine bismuth citrate-containing therapy after H. pylori treatment failure. Helicobacter 2007, 12:68-73.
248. Perna F., Zullo A., Ricci C., Hassan C., Morini S., Vaira D. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis 2007, 39:1001-1005.
249. Gisbert J.P., Bermejo F., Castro-Fernandez M., Perez-Aisa A., Fernandez-Bermejo M., Tomas A., et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol 2008, 103:71-76.
250. Jung H.S., Shim K.N., Baik S.J., Na Y.J., Kang M.J., Jung J.M., et al. Efficacy of levofloxacin-based triple therapy as second-line Helicobacter pylori eradication. Korean J Gastroenterol 2008, 51:285-290.
251. di Caro S., Franceschi F., Mariani A., Thompson F., Raimondo D., Masci E., et al. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Dig Liver Dis 2009, 41:480-485.
252. Kuo C.H., Hu H.M., Kuo F.C., Hsu P.I., Chen A., Yu F.J., et al. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother 2009, 63:1017-1024.
253. Schrauwen R.W., Janssen M.J., de Boer W.A. Seven-day PPI-triple therapy with levofloxacin is very effective for Helicobacter pylori eradication. Neth J Med 2009, 67:96-101.
254. Liou J.M., Lin J.T., Chang C.Y., Chen M.J., Cheng T.Y., Lee Y.C., et al. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut 2010, 59:572-578.
255. Zullo A., de Francesco V., Manes G., Scaccianoce G., Cristofari F., Hassan C. Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice. J Gastrointestin Liver Dis 2010, 19:131-134.
256. Gisbert JP, Perez-Aisa A, Bermejo F, Castro-Fernandez M, Almela P, Barrio J, et al. Second-line therapy with levofloxacin after failure of treatment to eradicate Helicobacter pylori infection: time trends in a spanish multicenter study of 1000 patients. J Clin Gastroenterol. 2013;47:130-5.
257. Gisbert J.P., Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006, 23:35-44.
258. Saad R.J., Schoenfeld P., Kim H.M., Chey W.D. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006, 101:488-496.
259. Li Y., Huang X., Yao L., Shi R., Zhang G. Advantages of moxifloxacin and levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr 2010, 122:413-422.
260. Marín A.C., McNicholl A.G., Gisbert J.P. Metaanálisis: triple terapia con levofloxacino vs. cuádruple terapia con bismuto como tratamientos de rescate de segunda línea para la erradicación de Helicobacter pylori. Gastroenterol Hepatol 2012, 35:104.
261. Gisbert JP, Molina-Infante J, Marín AC, Vinagre G, Barrio J, McNicholl AG. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection. Scand J Gastroenterol. 2013. En prensa.
262. Zullo A., de Francesco V., Hassan C. Second-line treatment for Helicobacter pylori eradication after sequential therapy failure: a pilot study. Therapy 2006, 3:251-254.
263. Pontone S., Standoli M., Angelini R., Pontone P. Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice. Dig Liver Dis 2010, 42:541-543.
264. Manfredi M., Bizzarri B., De'angelis G.L. Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate. Helicobacter 2012, 17:246-253.
265. Gisbert J.P. Rescue therapy after Helicobacter pylori eradication failure. Gastroenterol Hepatol 2011, 34:89-99.
266. Gisbert JP, Perez-Aisa A, Rodrigo L, Molina-Infante J, Modolell I, Bermejo F, et al. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) to eradicate Helicobacter pylori infection. Helicobacter. 2012;17(Suppl 1):P4.11.
267. Gomollon F., Sicilia B., Ducons J.A., Sierra E., Revillo M.J., Ferrero M. Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. Aliment Pharmacol Ther 2000, 14:1335-1338.
268. Vicente R., Sicilia B., Gallego S., Revillo M.J., Ducons J., Gomollon F. Helicobacter pylori eradication in patients with peptic ulcer after two treatment failures: a prospective culture-guided study. Gastroenterol Hepatol 2002, 25:438-442.
269. Cammarota G., Martino A., Pirozzi G., Cianci R., Branca G., Nista E.C., et al. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther 2004, 19:789-795.
270. Gisbert J.P., Pajares J.M. Helicobacter pylori «rescue» therapy after failure of two eradication treatments. Helicobacter 2005, 10:363-372.
271. Gisbert J.P., Castro-Fernandez M., Bermejo F., Perez-Aisa A., Ducons J., Fernandez-Bermejo M., et al. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol 2006, 101:243-247.
272. Gisbert J.P. Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection. Aliment Pharmacol Ther 2012, 35:1484-1485.
273. Gatta L., Zullo A., Perna F., Ricci C., de Francesco V., Tampieri A., et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005, 22:45-49.
274. Gisbert J.P., Gisbert J.L., Marcos S., Moreno-Otero R., Pajares J.M. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther 2006, 24:1469-1474.
275. Rokkas T., Sechopoulos P., Robotis I., Margantinis G., Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009, 104:21-25.
276. Maddix D.S., Tallian K.B., Mead P.S. Rifabutin: a review with emphasis on its role in the prevention of disseminated Mycobacterium avium complex infection. Ann Pharmacother 1994, 28:1250-1254.
277. Gisbert J.P., Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012, 35:209-221.
278. Bock H., Koop H., Lehn N., Heep M. Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience. J Clin Gastroenterol 2000, 31:222-225.
279. Canducci F., Ojetti V., Pola P., Gasbarrini G., Gasbarrini A. Rifabutin-based Helicobacter pylori eradication «rescue therapy». Aliment Pharmacol Ther 2001, 15:143.
280. Miehlke S., Schneider-Brachert W., Kirsch C., Morgner A., Madisch A., Kuhlisch E., et al. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2008, 13:69-74.
281. Perri F., Festa V., Clemente R., Quitadamo M., Andriulli A. Rifabutin-based «rescue therapy» for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000, 14:311-316.
282. van der Poorten D., Katelaris P.H. The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment Pharmacol Ther 2007, 26:1537-1542.
283. van Zanten S.V., Desai S., Best L., Cooper-Lesins G., Malatjalian D., Haldane D., et al. Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection. Can J Gastroenterol 2010, 24:303-306.
284. Gisbert J.P., Castro-Fernandez M., Perez-Aisa A., Cosme A., Molina-Infante J., Rodrigo L., et al. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther 2012, 35:941-947.
285. Gisbert J.P., Gisbert J.L., Marcos S., Olivares D., Pajares J.M. Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol Ther 2005, 22:1041-1046.
286. Gisbert J.P., Perez-Aisa A., Castro-Fernandez M., Barrio J., Rodrigo L., Cosme A., et al. Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. Dig Liver Dis 2010, 42:287-290.
287. Gisbert J.P., Pérez-Aisa A., Castro-Fernández M., Barrio J., Rodrigo L., Cosme A., et al. Tratamiento erradicador de H. pylori de primera línea con claritromicina y metronidazol en pacientes alérgicos a la penicilina: ¿es una opción aceptable en nuestro medio?. Gastroenterol Hepatol 2012, 35:99.
288. Gisbert J.P., Gonzalez L., Calvet X., Garcia N., Lopez T., Roque M., et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000, 14:1319-1328.
289. Gisbert J.P., Maria Pajares J. Helicobacter pylori resistance to metronidazole and to clarithromycin in Spain. A systematic review. Med Clin (Barc) 2001, 116:111-116.
290. Rodriguez-Torres M., Salgado-Mercado R., Rios-Bedoya C.F., Aponte-Rivera E., Marxuach-Cuetara A.M., Rodriguez-Orengo J.F., et al. High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin. Dig Dis Sci 2005, 50:634-639.
291. Gisbert J.P., Pérez-Aisa A., Castro-Fernández M., Barrio J., Rodrigo L., Cosme A., et al. Tratamiento erradicador de H. pylori de rescate basado en levofloxacino en pacientes alérgicos a la penicilina en los que previamente ha fracasado un tratamiento con claritromicina y metronidazol. Gastroenterol Hepatol 2011, 34:233.
292. Colin R. Duodenal ulcer healing with 1-week eradication triple therapy followed, or not, by anti-secretory treatment: a multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 2002, 16:1157-1162.
293. Hsu C.C., Lu S.N., Changchien C.S. One-week low-dose triple therapy without anti-acid treatment has sufficient efficacy on Helicobacter pylori eradication and ulcer healing. Hepatogastroenterology 2003, 50:1731-1734.
294. Labenz J., Idstrom J.P., Tillenburg B., Peitz U., Adamek R.J., Borsch G. One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. Aliment Pharmacol Ther 1997, 11:89-93.
295. Marzio L., Cellini L., Angelucci D. Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacter pylori infection. A double blind placebo controlled trial. Dig Liver Dis 2003, 35:20-23.
296. Tepes B., Krizman I., Gorensek M., Gubina M., Orel I. Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer?. Aliment Pharmacol Ther 2001, 15:1037-1045.
297. Tulassay Z., Kryszewski A., Dite P., Kleczkowski D., Rudzinski J., Bartuzi Z., et al. One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur J Gastroenterol Hepatol 2001, 13:1457-1465.
298. Subei I.M., Cardona H.J., Bachelet E., Useche E., Arigbabu A., Hammour A.A., et al. One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healding in Helicobacter pylori-positive patients. Dig Dis Sci 2007, 52:1505-1512.
299. Treiber G., Lambert J.R. The impact of Helicobacter pylori eradication on peptic ulcer healing. Am J Gastroenterol 1998, 93:1080-1084.
300. Leodolter A., Kulig M., Brasch H., Meyer-Sabellek W., Willich S.N., Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001, 15:1949-1958.
301. Higuchi K., Fujiwara Y., Tominaga K., Watanabe T., Shiba M., Nakamura S., et al. Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. Aliment Pharmacol Ther 2003, 17:111-117.
302. Lai K.C., Hui W.M., Wong B.C., Hu W.H., Lam S.K. Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. Aliment Pharmacol Ther 2000, 14:1071-1076.
303. Chan F.K., Wong V.W., Suen B.Y., Wu J.C., Ching J.Y., Hung L.C., et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007, 369:1621-1626.
304. Chan F.K., Hung L.C., Suen B.Y., Wong V.W., Hui A.J., Wu J.C., et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004, 127:1038-1043.
305. Gisbert J.P., Pajares J.M. Helicobacter pylori and bleeding peptic ulcer: what is the prevalence of the infection in patients with this complication?. Scand J Gastroenterol 2003, 38:2-9.
306. Gisbert J.P., Khorrami S., Carballo F., Calvet X., Gene E., Dominguez-Munoz E. Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther 2004, 19:617-629.
307. Amendola M., Farias R., Katz J., Luna P., Ianella M., Musi A., et al. Absence of bleeding recurrence of peptic ulcer after long term follow-up of successful eradication of Helicobacter pylori. Acta Gastroenterol Latinoam 1999, 29:47-50.
308. Arkkila P.E., Seppala K., Kosunen T.U., Haapiainen R., Kivilaakso E., Sipponen P., et al. Eradication of Helicobacter pylori improves the healing rate and reduces the relapse rate of nonbleeding ulcers in patients with bleeding peptic ulcer. Am J Gastroenterol 2003, 98:2149-2156.
309. Capurso G., Annibale B., Osborn J., D'Ambra G., Martino G., Lahner E., et al. Occurrence and relapse of bleeding from duodenal ulcer: respective roles of acid secretion and Helicobacter pylori infection. Aliment Pharmacol Ther 2001, 15:821-829.
310. Gisbert J.P., Boixeda D., Aller R., de la Serna C., Sanz E., Martin de Argila C., et al. Helicobacter pylori and digestive hemorrhage due to duodenal ulcer: the prevalence of the infection, the efficacy of 3 triple therapies and the role of eradication in preventing a hemorrhagic recurrence. Med Clin (Barc) 1999, 112:161-165.
311. Graham D.Y., Hepps K.S., Ramirez F.C., Lew G.M., Saeed Z.A. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 1993, 28:939-942.
312. Horvat D., Vcev A., Soldo I., Timarac J., Dmitrovic B., Misevic T., et al. The results of Helicobacter pylori eradication on repeated bleeding in patients with stomach ulcer. Coll Antropol 2005, 29:139-142.
313. Jaspersen D., Koerner T., Schorr W., Brennenstuhl M., Raschka C., Hammar C.H. Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage. Gastrointest Endosc 1995, 41:5-7.
314. Jaspersen D., Korner T., Schorr W., Brennenstuhl M., Hammar C.H. Omeprazole-amoxycillin therapy for eradication of Helicobacter pylori in duodenal ulcer bleeding: preliminary results of a pilot study. J Gastroenterol 1995, 30:319-321.
315. Krizman I., Ribnikar M., Kozjek F., Primozic S. Comparative amoxicillin - Azithromycin treatment of Helicobacter pylori positive patients with bleeding duodenal ulcer. Acta Pharmaceutica 1997, 47:183-188.
316. Labenz J., Borsch G. Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion 1994, 55:19-23.
317. Lai K.C., Hui W.M., Wong W.M., Wong B.C., Hu W.H., Ching C.K., et al. Treatment of Helicobacter pylori in patients with duodenal ulcer hemorrhage--a long-term randomized, controlled study. Am J Gastroenterol 2000, 95:2225-2232.
318. Liu C.C., Lee C.L., Chan C.C., Tu T.C., Liao C.C., Wu C.H., et al. Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study. Arch Intern Med 2003, 163:2020-2024.
319. Macri G., Milani S., Surrenti E., Passaleva M.T., Salvadori G., Surrenti C. Eradication of Helicobacter pylori reduces the rate of duodenal ulcer rebleeding: a long-term follow-up study. Am J Gastroenterol 1998, 93:925-927.
320. Pellicano R., Peyre S., Leone N., Repici A., de Angelis C., Rizzi R., et al. The effect of the eradication of Helicobacter pylori infection on hemorrhage because of duodenal ulcer. J Clin Gastroenterol 2001, 32:222-224.
321. Riemann J.F., Schilling D., Schauwecker P., Wehlen G., Dorlars D., Kohler B., et al. Cure with omeprazole plus amoxicillin versus long-term ranitidine therapy in Helicobacter pylori-associated peptic ulcer bleeding. Gastrointest Endosc 1997, 46:299-304.
322. Rokkas T., Karameris A., Mavrogeorgis A., Rallis E., Giannikos N. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. Gastrointest Endosc 1995, 41:1-4.
323. Santander C., Gravalos R.G., Gomez-Cedenilla A., Cantero J., Pajares J.M. Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. Am J Gastroenterol 1996, 91:1549-1552.
324. Sung J.J., Leung W.K., Suen R., Leung V.K., Chan F.K., Ling T.K., et al. One-week antibiotics versus maintenance acid suppression therapy for Helicobacter pylori-associated peptic ulcer bleeding. Dig Dis Sci 1997, 42:2524-2528.
325. Vcev A., Horvat D., Rubinic M., Stimac D., Vceva A., Uravic M., et al. Eradication of Helicobacter pylori reduces the possibility of rebleeding in duodenal ulcer disease. Acta Fam Med Flum 1996, 21:59-65.
326. Vergara M., Casellas F., Saperas E., de Torres I., Lopez J., Borruel N., et al. Helicobacter pylori eradication prevents recurrence from peptic ulcer haemorrhage. Eur J Gastroenterol Hepatol 2000, 12:733-737.